DISCUSSION:
Is there an unmet medical need for systemic products (drugs and biologics) approved for treatment of children with atopic dermatitis that is inadequately responsive to topical therapy? 2. DISCUSSION: How much evidence of treatment effect and safety should be obtained in adults prior to studying the use of a novel agent in the treatment of children with atopic dermatitis that is inadequately responsive to topical therapy: − preliminary efficacy and safety data (early-phase trial/s)? − determinative efficacy and safety data (phase 3 trials)? − post-marketing adverse event data?
3. DISCUSSION: How much uncertainty about the potential risks and benefits of novel agents is tolerable when initiating a pediatric trial, given the nature of the disease (severity, co-morbidities, impact on quality of life) and the risk-benefit calculus of available alternative treatments (e.g., systemic corticosteroids, cyclosporine, azathioprine, methotrexate, mycophenolate mofetil)? Address whether enrollment of pediatric subjects would be acceptable prior to the resolution of questions regarding potential risk for low-frequency or long-latency adverse events.
Describe the appropriate pediatric population in whom to study systemic treatments such that the risks and potential benefits of the investigational agent could be compared to the population who receive alternative treatments (e.g., systemic corticosteroids, cyclosporine, azathioprine, methotrexate, mycophenolate mofetil). Address disease severity, prior treatment, age, and any other relevant factors.
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Page 2 of 2 5. DISCUSSION: Address the importance of having sufficient data to label the product for use in some or all pediatric subpopulations at the time of an adult approval in order to avoid the risks of "off-label" use in children.
6. DISCUSSION: Describe the age range that should be studied, and address whether older pediatric subpopulations should be studied prior to or concurrently with younger pediatric subpopulations (e.g., 12-<17 years, 6-<12 years, 2-<6 years, 6 months -<2 years)?
